In a recent study conducted in an adult population, patients with higher levels of serum IGF1 and with a higher IGF1/IGFBP-3 ratio had a lower risk of NASH, while patients with obesity with/without MAFLD always had lower serum IGF1 levels [33]. This evidence concerns the gene IGF1 and metabolic dysfunction-associated steatohepatitis.